- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 854846, 8 pages
Mesenchymal Stem Cells as Immunomodulators in a Vascularized Composite Allotransplantation
1Center for Vascularized Composite Allotransplantation, Kaohsiung Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Kaohsiung 833, Taiwan
2Department of Plastic and Reconstructive Surgery, Kaohsiung Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Kaohsiung 833, Taiwan
3Liver Transplantation Program and Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Kaohsiung 833, Taiwan
Received 29 June 2012; Revised 22 September 2012; Accepted 23 September 2012
Academic Editor: Gerald Brandacher
Copyright © 2012 Yur-Ren Kuo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- W. P. A. Lee, “Composite tissue transplantation: more science and patience needed,” Plastic and Reconstructive Surgery, vol. 107, no. 4, pp. 1066–1070, 2001.
- J. M. Dubernard and B. Devauchelle, “Face transplantation,” The Lancet, vol. 372, no. 9639, pp. 603–604, 2008.
- J. W. Jones, S. A. Gruber, J. H. Barker, and W. C. Breidenbach, “Successful hand transplantation: one-year follow-up,” The New England Journal of Medicine, vol. 343, no. 7, pp. 468–473, 2000.
- C. L. Kaufman and W. Breidenbach, “World experience after more than a decade of clinical hand transplantation: update from the Louisville hand transplant program,” Hand Clinics, vol. 27, no. 4, pp. 417–421, 2011.
- M. Siemionow and C. Ozturk, “An update on facial transplantation cases performed between 2005 and 2010,” Plastic and Reconstructive Surgery, vol. 128, pp. 707e–720e, 2011.
- J. T. Shores, J. E. Imbriglia, and W. P. Lee, “The current state of hand transplantation,” American Journal of Hand Surgery, vol. 36, pp. 1862–1867, 2011.
- W. P. A. Lee, M. J. Yaremchuk, Y. C. Pan, M. A. Randolph, C. M. Tan, and A. J. Weiland, “Relative antigenicity of components of a vascularized limb allograft,” Plastic and Reconstructive Surgery, vol. 87, no. 3, pp. 401–411, 1991.
- H. Madani, S. Hettiaratchy, A. Clarke, and P. E. M. Butler, “Immunosuppression in an emerging field of plastic reconstructive surgery: composite tissue allotransplantation,” Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 61, no. 3, pp. 245–249, 2008.
- S. Schneeberger, V. S. Gorantla, R. P. van Riet et al., “Atypical acute rejection after hand transplantation,” American Journal of Transplantation, vol. 8, no. 3, pp. 688–696, 2008.
- C. L. Kaufman, R. Ouseph, B. Blair, et al., “Graft vasculopathy in clinical hand transplantation,” American Journal of Transplantation, vol. 12, no. 4, pp. 1004–1016, 2012.
- K. Ravindra, M. Haeberle, L. S. Levin, and S. T. Ildstad, “Immunology of vascularized composite allotransplantation: a primer for hand surgeons,” American Journal of Hand Surgery, vol. 37, no. 4, pp. 842–850, 2012.
- N. Arima, F. Nakamura, A. Fukunaga et al., “Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study,” Cytotherapy, vol. 12, no. 2, pp. 265–268, 2010.
- A. Bacigalupo, “Management of acute graft-versus-host disease,” British Journal of Haematology, vol. 137, no. 2, pp. 87–98, 2007.
- G. W. Dryden Jr., “Overview of biologic therapy for Crohn's disease,” Expert Opinion on Biological Therapy, vol. 9, no. 8, pp. 967–974, 2009.
- J. Dalal, K. Gandy, and J. Domen, “Role of mesenchymal stem cell therapy in Crohn's disease,” Pediatric Research, vol. 71, no. 4, pp. 445–451, 2012.
- G. Lanzoni, G. Roda, A. Belluzi, E. Roda, and G. P. Bagnara, “Inflammatory bowel disease: moving toward a stem cell-based therapy,” World Journal of Gastroenterology, vol. 14, no. 29, pp. 4616–4626, 2008.
- P. Connick, M. Kolappan, C. Crawley, et al., “Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study,” The Lancet Neurology, vol. 11, no. 2, pp. 150–156, 2012.
- D. Karussis, C. Karageorgiou, A. Vaknin-Dembinsky et al., “Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis,” Archives of Neurology, vol. 67, no. 10, pp. 1187–1194, 2010.
- J. Liang, H. Zhang, B. Hua, et al., “Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study,” Annals of the Rheumatic Diseases, vol. 69, no. 8, pp. 1423–1429, 2010.
- D. Shi, D. Wang, X. Li, et al., “Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus,” Clinical Rheumatology, vol. 31, no. 5, pp. 841–846, 2012.
- A. J. Friedenstein, U. F. Gorskaja, and N. N. Kulagina, “Fibroblast precursors in normal and irradiated mouse hematopoietic organs,” Experimental Hematology, vol. 4, no. 5, pp. 267–274, 1976.
- M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999.
- Y. R. Kuo, C. T. Wang, J. T. Cheng, F. S. Wang, Y. C. Chiang, and C. J. Wang, “Bone marrow-derived mesenchymal stem cells enhanced diabetic wound healing through recruitment of tissue regeneration in a rat model of streptozotocin-induced diabetes,” Plastic and Reconstructive Surgery, vol. 128, no. 4, pp. 872–880, 2011.
- M. Crisan, S. Yap, L. Casteilla et al., “A perivascular origin for mesenchymal stem cells in multiple human organs,” Cell Stem Cell, vol. 3, no. 3, pp. 301–313, 2008.
- A. I. Caplan, “Mesenchymal stem cells,” Journal of Orthopaedic Research, vol. 9, no. 5, pp. 641–650, 1991.
- P. S. In't Anker, S. A. Scherjon, C. Kleijburg-van der Keur et al., “Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta,” Stem Cells, vol. 22, no. 7, pp. 1338–1345, 2004.
- K. Bieback, S. Kern, H. Klüter, and H. Eichler, “Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood,” Stem Cells, vol. 22, no. 4, pp. 625–634, 2004.
- P. A. Zuk, M. Zhu, H. Mizuno et al., “Multilineage cells from human adipose tissue: implications for cell-based therapies,” Tissue Engineering, vol. 7, no. 2, pp. 211–228, 2001.
- R. J. Deans and A. B. Moseley, “Mesenchymal stem cells: biology and potential clinical uses,” Experimental Hematology, vol. 28, no. 8, pp. 875–884, 2000.
- M. Krampera, S. Glennie, J. Dyson et al., “Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide,” Blood, vol. 101, no. 9, pp. 3722–3729, 2003.
- S. Glennie, I. Soeiro, P. J. Dyson, E. W. F. Lam, and F. Dazzi, “Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells,” Blood, vol. 105, no. 7, pp. 2821–2827, 2005.
- I. Rasmusson, O. Ringdén, B. Sundberg, and K. Le Blanc, “Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells,” Transplantation, vol. 76, no. 8, pp. 1208–1213, 2003.
- M. D. Nicola, C. Carlo-Stella, M. Magni et al., “Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli,” Blood, vol. 99, no. 10, pp. 3838–3843, 2002.
- Y. R. Kuo, C. C. Chen, S. Goto, et al., “Modulation of immune response and T-cell regulation by donor adipose-derived stem cells in a rodent hind-limb allotransplant model,” Plastic and Reconstructive Surgery, vol. 128, no. 6, pp. 661e–672e, 2011.
- Y. R. Kuo, C. C. Chen, H. S. Shih et al., “Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with T-cell regulation in a swine hind-limb model,” Plastic and Reconstructive Surgery, vol. 127, no. 2, pp. 569–579, 2011.
- P. J. Coffer and B. M. T. Burgering, “Forkhead-box transcription factors and their role in the immune system,” Nature Reviews Immunology, vol. 4, no. 11, pp. 889–899, 2004.
- H. von Boehmer, “Mechanisms of suppression by suppressor T cells,” Nature Immunology, vol. 6, no. 4, pp. 338–344, 2005.
- S. Sakaguchi, “Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses,” Annual Review of Immunology, vol. 22, pp. 531–562, 2004.
- Z. Fehérvári and S. Sakaguchi, “Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells,” International Immunology, vol. 16, no. 12, pp. 1769–1780, 2004.
- A. J. Nauta and W. E. Fibbe, “Immunomodulatory properties of mesenchymal stromal cells,” Blood, vol. 110, no. 10, pp. 3499–3506, 2007.
- H. Yagi, A. Soto-Gutierrez, B. Parekkadan et al., “Mesenchymal stem cells: mechanisms of immunomodulation and homing,” Cell Transplantation, vol. 19, no. 6-7, pp. 667–679, 2010.
- S. Aggarwal and M. F. Pittenger, “Human mesenchymal stem cells modulate allogeneic immune cell responses,” Blood, vol. 105, no. 4, pp. 1815–1822, 2005.
- Y. H. Kim, Y. M. Wee, M. Y. Choi, D. G. Lim, S. C. Kim, and D. J. Han, “Interleukin (IL)-10 induced by CD11b+ cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts,” Molecular Medicine, vol. 17, no. 7-8, pp. 697–708, 2011.
- K. English, J. M. Ryan, L. Tobin, M. J. Murphy, F. P. Barry, and B. P. Mahon, “Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells,” Clinical and Experimental Immunology, vol. 156, no. 1, pp. 149–160, 2009.
- U. Hainz, B. Jürgens, and A. Heitger, “The role of indoleamine 2,3-dioxygenase in transplantation,” Transplant International, vol. 20, no. 2, pp. 118–127, 2007.
- R. Meisel, A. Zibert, M. Laryea, U. Göbel, W. Däubener, and D. Dilloo, “Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation,” Blood, vol. 103, no. 12, pp. 4619–4621, 2004.
- R. Maccario, A. Moretta, A. Cometa et al., “Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes,” Biology of Blood and Marrow Transplantation, vol. 11, no. 12, pp. 1031–1032, 2005.
- S. Beyth, Z. Borovsky, D. Mevorach et al., “Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness,” Blood, vol. 105, no. 5, pp. 2214–2219, 2005.
- A. W. Thomson, “Tolerogenic dendritic cells: all present and correct?” American Journal of Transplantation, vol. 10, no. 2, pp. 214–219, 2010.
- P. T. H. Coates, B. L. Colvin, K. Kaneko, T. Taner, and A. W. Thomson, “Pharmacologic, biologic, and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity,” Transplantation, vol. 75, no. 9, supplement, pp. 32S–36S, 2003.
- Y. J. Jung, S. Y. Ju, E. S. Yoo et al., “MSC-DC interactions: MSC inhibit maturation and migration of BM-derived DC,” Cytotherapy, vol. 9, no. 5, pp. 451–458, 2007.
- P. A. Morel, M. Feili-Hariri, P. T. Coates, and A. W. Thomson, “Dendritic cells, T cell tolerance and therapy of adverse immune reactions,” Clinical and Experimental Immunology, vol. 133, no. 1, pp. 1–10, 2003.
- Y. R. Kuo, C. W. Huang, S. Goto et al., “Alloantigen-pulsed host dendritic cells induce T-cell regulation and prolong allograft survival in a rat model of hindlimb allotransplantation,” Journal of Surgical Research, vol. 153, no. 2, pp. 317–325, 2009.
- W. E. Fibbe, A. J. Nauta, and H. Roelofs, “Modulation of immune responses by mesenchymal stem cells,” Annals of the New York Academy of Sciences, vol. 1106, pp. 272–278, 2007.
- X. X. Jiang, Y. Zhang, B. Liu et al., “Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells,” Blood, vol. 105, no. 10, pp. 4120–4126, 2005.
- R. Yañez, M. L. Lamana, J. García-Castro, I. Colmenero, M. Ramírez, and J. A. Bueren, “Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease,” Stem Cells, vol. 24, no. 11, pp. 2582–2591, 2006.
- O. Ringdén, M. Uzunel, I. Rasmusson et al., “Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease,” Transplantation, vol. 81, no. 10, pp. 1390–1397, 2006.
- K. English, A. French, and K. J. Wood, “Mesenchymal stromal cells: facilitators of successful transplantation?” Cell Stem Cell, vol. 7, no. 4, pp. 431–442, 2010.
- A. Bartholomew, C. Sturgeon, M. Siatskas et al., “Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo,” Experimental Hematology, vol. 30, no. 1, pp. 42–48, 2002.
- P. Sbano, A. Cuccia, B. Mazzanti et al., “Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model,” Archives of Dermatological Research, vol. 300, no. 3, pp. 115–124, 2008.
- H. Pan, K. Zhao, L. Wang et al., “Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation,” Journal of Surgical Research, vol. 160, no. 2, pp. 315–324, 2010.
- Y. R. Kuo, J. M. Sacks, W. P. A. Lee et al., “Porcine heterotopic composite tissue allograft transplantation using a large animal model for preclinical studies,” Chang Gung Medical Journal, vol. 29, no. 3, pp. 268–274, 2006.
- Y. R. Kuo, S. Goto, H. S. Shih et al., “Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model,” Transplantation, vol. 87, no. 12, pp. 1769–1777, 2009.
- F. Casiraghi, N. Azzollini, P. Cassis et al., “Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells,” The Journal of Immunology, vol. 181, no. 6, pp. 3933–3946, 2008.
- S. Itakura, S. Asari, J. Rawson et al., “Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat,” American Journal of Transplantation, vol. 7, no. 2, pp. 336–346, 2007.
- Y. R. Kuo, C. C. Chen, S. Goto, et al., “Immunomodulatory effects of bone marrow-derived mesenchymal stem cells in a Swine hemi-facial allotransplantation model,” PLoS One, vol. 7, no. 4, Article ID e35459, 2012.
- W. Ge, J. Jiang, M. L. Baroja, et al., “Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance,” American Journal of Transplantation, vol. 9, no. 8, pp. 1760–1772, 2009.
- Y. R. Kuo, H. S. Shih, C. C. Lin et al., “Swine hemi-facial composite tissue allotransplantation: a model to study immune rejection,” Journal of Surgical Research, vol. 153, no. 2, pp. 268–273, 2009.
- C. Prevosto, M. Zancolli, P. Canevali, M. R. Zocchi, and A. Poggi, “Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction,” Haematologica, vol. 92, no. 7, pp. 881–888, 2007.